CagriSema Phase 3 Trial Investigates Long-Term Weight Loss for Obesity

Globally, obesity remains a significant public health challenge, associated with numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. While existing treatments offer varying degrees of success, there's a continuous need for more effective and sustainable long-term weight management solutions. This Phase 3 clinical trial aims to address this by evaluating the long-term efficacy and safety of CagriSema, a novel combination therapy, for sustained weight loss and maintenance in individuals with obesity.

This Phase 3 trial aims to rigorously evaluate the efficacy and safety of CagriSema for weight management and long-term weight maintenance in individuals with obesity. The primary endpoint is the change in body weight from baseline to week 72. The study's most critical objective is to determine if CagriSema can induce a statistically significant and clinically meaningful reduction in body weight compared to placebo over an extended period. Secondary objectives include assessing the proportion of participants achieving specific weight loss thresholds (e.g., ≥5%, ≥10%, ≥15% body weight reduction), changes in body composition (fat mass, lean mass), and improvements in cardiometabolic risk factors such as blood pressure, lipid profiles, and glycemic control. The trial will also meticulously monitor adverse events to establish the long-term safety profile and tolerability of the combination therapy.